AAAAAA

   
Results: 1-10 |
Results: 10
Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene
Authors: Fischereder, M Schneeberger, H Lohse, P Kramer, BK Schlondorff, D Land, W
Citation: M. Fischereder et al., Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene, AM J KIDNEY, 38(5), 2001, pp. 1061-1064
CC chemokine receptor 5 and renal-transplant survival
Authors: Fischereder, M Luckow, B Hocher, B Wuthrich, RP Rothenpieler, U Schneeberger, H Panzer, U Stahl, RAK Hauser, IA Budde, K Neumayer, HH Kramer, BK Land, W Schlondorff, D
Citation: M. Fischereder et al., CC chemokine receptor 5 and renal-transplant survival, LANCET, 357(9270), 2001, pp. 1758-1761
Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts
Authors: Lederer, SR Kluth-Pepper, B Schneeberger, H Albert, E Land, W Feucht, HE
Citation: Sr. Lederer et al., Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts, KIDNEY INT, 59(1), 2001, pp. 334-341
Mycophenolate mofetil monotherapy: An optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients
Authors: Land, W Schneeberger, H Weiss, M Ege, T Stumpfig, L
Citation: W. Land et al., Mycophenolate mofetil monotherapy: An optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients, TRANSPLAN P, 33(4), 2001, pp. 29S-35S
Influence of brain death on cytokine release in organ donors and renal transplants
Authors: Stangl, M Zerkaulen, T Theodorakis, J Illner, W Schneeberger, H Land, W Faist, E
Citation: M. Stangl et al., Influence of brain death on cytokine release in organ donors and renal transplants, TRANSPLAN P, 33(1-2), 2001, pp. 1284-1285
Mycophenolate mofetil monotherapy: An example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients
Authors: Keunecke, C Rothenpieler, U Zanker, B Schneeberger, H Illner, WD Theodorakis, J Stangl, M Land, W
Citation: C. Keunecke et al., Mycophenolate mofetil monotherapy: An example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients, TRANSPLAN P, 32(1A), 2000, pp. 6S-8S
Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors
Authors: Theodorakis, J Schneeberger, H Illner, WD Stangl, M Zanker, B Land, W
Citation: J. Theodorakis et al., Nephrotoxicity-free, mycophenolate mofetil-based induction/maintenance immunosuppression in elderly recipients of renal allografts from elderly cadaveric donors, TRANSPLAN P, 32(1A), 2000, pp. 9S-11S
Early graft failure with thrombophilia and effects of anticoagulation
Authors: Fischereder, M Schneeberger, H Gohring, P Hillebrand, G Schlondorff, D Land, W
Citation: M. Fischereder et al., Early graft failure with thrombophilia and effects of anticoagulation, TRANSPLAN P, 31(1-2), 1999, pp. 360-361
Nonnephrotoxic, nonatherogenic maintenance therapy in kidney-transplanted patients using MMF-monotherapy: A pilot study
Authors: Zanker, B Rothenpieler, U Kubitza, A Schneeberger, H Hillebrand, G Land, W
Citation: B. Zanker et al., Nonnephrotoxic, nonatherogenic maintenance therapy in kidney-transplanted patients using MMF-monotherapy: A pilot study, TRANSPLAN P, 31(1-2), 1999, pp. 1142-1143
No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure
Authors: Hillebrand, GF Schlosser, S Schneeberger, H Lorenz, B Zanker, B Samtleben, W Land, W
Citation: Gf. Hillebrand et al., No clinical evidence of hyperlipidemia as a risk factor for chronic renal allograft failure, TRANSPLAN P, 31(1-2), 1999, pp. 1391-1392
Risultati: 1-10 |